HRCM
NBIX icon

Hood River Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Hood River Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.1M Buy
469,233
+64,840
+16% +$9.62M 0.57% 62
2026
Q1 		$53.3M Buy
404,393
+15,096
+4% +$2M 0.53% 64
2025
Q4 		$55.2M Sell
389,297
-112,194
-22% -$16.3M 0.61% 60
2025
Q3 		$70.4M Buy
501,491
+243,953
+95% +$33.1M 0.83% 46
2025
Q2 		$32.4M Sell
257,538
-79,626
-24% -$9.13M 0.45% 78
2025
Q1 		$37.3M Sell
337,164
-17,894
-5% -$2.27M 0.64% 66
2024
Q4 		$48.5M Buy
355,058
+91,848
+35% +$11.4M 0.72% 55
2024
Q3 		$30.3M Buy
263,210
+19,313
+8% +$2.65M 0.49% 76
2024
Q2 		$33.6M Buy
243,897
+15,899
+7% +$2.18M 0.7% 55
2024
Q1 		$31.4M Buy
227,998
+15,608
+7% +$2.13M 0.7% 58
2023
Q4 		$28M Buy
212,390
+1,093
+0.5% +$126K 0.77% 54
2023
Q3 		$23.8M Sell
211,297
-1,793
-0.8% -$189K 0.76% 55
2023
Q2 		$20.1M Buy
213,090
+7,046
+3% +$688K 0.6% 65
2023
Q1 		$20.9M Buy
206,044
+6,356
+3% +$661K 0.68% 56
2022
Q4 		$23.9M Buy
199,688
+5,282
+3% +$619K 0.87% 48
2022
Q3 		$20.6M Buy
194,406
+3,678
+2% +$373K 0.79% 47
2022
Q2 		$18.6M Buy
190,728
+10,171
+6% +$939K 0.74% 55
2022
Q1 		$16.9M Buy
180,557
+3,689
+2% +$313K 0.56% 59
2021
Q4 		$15.1M Sell
176,868
-1,849
-1% -$170K 0.45% 70
2021
Q3 		$17.1M Buy
+178,717
New +$16.9M 0.53% 65
2020
Q2 		– Sell
-110,040
Closed -$9.52M – 114
2020
Q1 		$9.52M Buy
+110,040
New +$10.8M 0.54% 63
2017
Q2 		– Sell
-109,314
Closed -$4.73M – 94
2017
Q1 		$4.73M Sell
109,314
-96,015
-47% -$4.11M 0.36% 85
2016
Q4 		$7.95M Buy
205,329
+107,257
+109% +$4.86M 0.69% 63
2016
Q3 		$4.97M Sell
98,072
-40,935
-29% -$2.04M 0.51% 72
2016
Q2 		$6.32M Buy
139,007
+3,452
+3% +$159K 0.85% 52
2016
Q1 		$5.36M Buy
+135,555
New +$5.38M 0.72% 62

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hood River Capital Management's NBIX Position: Q2 2026 in Review

Hood River Capital Management increased its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, buying an estimated $9.62M and bringing the position to 469,233 shares worth $79.1M. The position accounts for 0.57% of the portfolio, ranked #62.

Hood River Capital Management first reported a position in NBIX in Q1 2016 and has held it in 26 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Hood River Capital Management held 469,233 shares of Neurocrine Biosciences worth $79.1M as of Q2 2026.
  • Hood River Capital Management bought 64,840 Neurocrine Biosciences shares in Q2 2026, an estimated $9.62M.
  • Neurocrine Biosciences made up 0.57% of Hood River Capital Management's portfolio in Q2 2026, its #62 holding.
  • Hood River Capital Management first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 26 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.